PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients


Autoria(s): Mangone, Flavia R.; Bobrovnitchaia, Irina G.; Salaorni, Sibeli; Manuli, Erika; Nagai, Maria A.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

02/10/2013

02/10/2013

2012

Resumo

OBJECTIVES: The phosphatidylinositol 3-kinase/AKT axis is an important cell-signaling pathway that mediates cell proliferation and survival, two biological processes that regulate malignant cell growth. The phosphatidylinositol 3-kinase CA gene encodes the p110 alpha subunit of the phosphatidylinositol 3-kinase protein. There are phosphatidylinositol 3-kinase CA mutations in several types of human tumors, and they are frequently observed in breast cancer. However, these mutations have not been investigated in Brazilian breast cancer patients. METHODS: PCR-SSCP and direct DNA sequencing were performed to identify phosphatidylinositol 3-kinaseCA exon 9 and exon 20 mutations in 86 patients with sporadic breast cancer. The relationships between PIK3CA mutations and patient clinicopathological characteristics and survival were analyzed. The presence of the TP53 mutation was also examined. RESULTS: Twenty-three (27%) of the 86 primary breast tumors contained PIK3CA mutations. In exons 9 and 20, we identified the hotspot mutations E542K, E545K, and H1047R, and we identified two new missense mutations (I1022V and L1028S) and one nonsense (R992X) mutation. Phosphatidylinositol 3-kinase CA exon 20 mutations were associated with poor overall survival and TP53 gene mutations. CONCLUSIONS: Phosphatidylinositol 3-kinase CA mutations are common in tumors in Brazilian breast cancer patients, and phosphatidylinositol 3-kinase CA and TP53 mutations are not mutually exclusive. Phosphatidylinositol 3-kinase CA exon 20 mutations are associated with poor survival, and they may be useful biomarkers for identifying breast cancer patients with aggressive tumors and for predicting the response to treatment with PI3K pathway inhibitors.

Departamento de Ciencia e Tecnologia-Ministerio da Saude/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [577587/2008-0 DECIT/CNPq]

Departamento de Ciencia e TecnologiaMinisterio da Saude/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

CNPq grant

CNPq grant [305408/2009-7]

Identificador

CLINICS, SAO PAULO, v. 67, n. 11, pp. 1285-1290, MAR, 2012

1807-5932

http://www.producao.usp.br/handle/BDPI/33975

10.6061/clinics/2012(11)11

http://dx.doi.org/10.6061/clinics/2012(11)11

Idioma(s)

eng

Publicador

HOSPITAL CLINICAS, UNIV SAO PAULO

SAO PAULO

Relação

CLINICS

Direitos

openAccess

Copyright HOSPITAL CLINICAS, UNIV SAO PAULO

Palavras-Chave #BREAST NEOPLASM #PIK3CA #TP53 #MUTATION #PROGNOSIS #CARCINOMAS #PATHWAY #PTEN #GENE #PI3K #MEDICINE, GENERAL & INTERNAL
Tipo

article

original article

publishedVersion